Government-Owned Inventions; Availability for Licensing, 14124-14125 [E7-5426]

Download as PDF 14124 Federal Register / Vol. 72, No. 57 / Monday, March 26, 2007 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources and Services Administration Agency Information Collection Activities: Proposed Collection: Comment Request In compliance with the requirement for opportunity for public comment on proposed data collection projects (section 3506(c)(2)(A) of Title 44, United States Code, as amended by the Paperwork Reduction Act of 1995, Pub. L. 104–13), the Health Resources and Services Administration (HRSA) publishes periodic summaries of proposed projects being developed for submission to the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995. To request more information on the proposed project or to obtain a copy of the data collection plans and draft instruments, call the HRSA Reports Clearance Officer on (301) 443–1129. Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Proposed Project: The National Health Service Corps (NHSC) Scholarship Program Deferment Request Forms and Associated Reporting Requirements (OMB No. 0915–0179): Extension The National Health Service Corps (NHSC) Scholarship program was established to assure an adequate supply of trained primary care health professionals to the neediest communities in Health Professional Shortage Areas (HPSAs) of the United States. Under the program, allopathic physicians, osteopathic physicians, dentists, nurse practitioners, nurse Number of respondents Form Responses per respondent midwives, physician assistants, and, if needed by the NHSC program, students of other health professions enter into a contractual agreement with the Secretary under which the Public Health Service agrees to pay the total school tuition, required fees and a stipend for living expenses. In exchange, the scholarship recipient agrees to provide full-time clinical services at a site in a federally designated HPSA. Once the scholars have met their academic requirements, the law requires that individuals receiving a degree from a school of medicine or osteopathic medicine must (and all others may) request a deferment of their service obligation to complete approved internship, residency or other advanced nursing training consistent with the needs of the NHSC. The Deferment Request Form and Letter of Intent and Request provide the information necessary for considering the period and type of training for which deferment of the service obligation is requested. The annual estimate of burden is as follows: Total responses Hours per response Total burden hours Deferment Request Form .................................................... Letters of Intent and Request .............................................. 600 100 1 1 600 100 1 1 600 100 Total .............................................................................. 700 ........................ 700 ........................ 700 Send comments to Susan G. Queen, Ph.D., HRSA Reports Clearance Officer, Room 10–33, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857. Written comments should be received within 60 days of this notice. Dated: March 19, 2007. Alexandra Huttinger, Acting Director, Division of Policy Review and Coordination. [FR Doc. E7–5414 Filed 3–23–07; 8:45 am] Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/ 496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. ADDRESSES: BILLING CODE 4165–15–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health cprice-sewell on PROD1PC66 with NOTICES Government-Owned Inventions; Availability for Licensing National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: Rapid Universal and/or Type-Specific Assay for Clostridium Botulinum The inventions listed below are owned by an agency of the U.S. Government and are available for SUMMARY: VerDate Aug<31>2005 15:30 Mar 23, 2007 Jkt 211001 licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. Description of Technology: The urgent need for a rapid diagnostic test capable of detecting all serotypes of C. botulinum is well known. Botulinum PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 neurotoxins (BoNTs) are the most potent biological toxins known and are categorized as category A biodefense agents because of lethality and ease of production. Current diagnostic methods include clinical observation of symptoms that could be mistaken for other neurological conditions and a mouse protection bioassay that takes as long as four days and has a number of disadvantages. The subject technology utilizes unique PCR primers for the detection of the non-toxin nonhemaglutinin (NTNH) gene of C. botulinum; this gene is highly conserved in all C. botulinum toxin types and subtypes. Thus, samples that contain botulinum can be determined regardless of serotype involved, providing a universal means of diagnosis. Further, the technology describes different PCR primers and flurogenic probes for a BoNT-specific assay. The type-specific assay can be used independently or in conjunction with the universal assay described above. The universal and type-specific assays were successfully used first to E:\FR\FM\26MRN1.SGM 26MRN1 Federal Register / Vol. 72, No. 57 / Monday, March 26, 2007 / Notices cprice-sewell on PROD1PC66 with NOTICES identify positively botulinum DNA samples in a test of botulinum and nonbotulinum clostridia species then to determine the toxin type. The diagnostic testing described by the subject technology requires significantly less time than the current gold standard diagnostic test. Applications: (1) Universal diagnostic test for C. botulinum; (2) Diagnostic test for C. botulinum capable of detecting all seven toxin types; (3) Combination diagnostic. Development Status: Fully developed. Inventors: Daniel C. Douek (VRC/ NIAID) et al. Patent Status: U.S. Provisional Application No. 60/884,539 filed 11 Jan 2007 (HHS Reference No. E–046–2007/ 0–US–01). Licensing Status: Available for nonexclusive or exclusive licensing. Licensing Contact: Susan Ano, Ph.D.; 301/435–5515; anos@mail.nih.gov. Methods and Compositions for Protecting Cells From UltrasoundMediated Cytolysis Description of Invention: Available for licensing and commercial development are methods for protecting cells from ultrasound-mediated cytolysis. The in vitro exposure of cells to ultrasound and the therapeutic uses of ultrasound (e.g., sonoporation, thrombolysis, HIFU, sonophoresis, acoustic hemostasis) may induce changes in tissue state, including apoptosis and cytolysis, through thermal effects (e.g., hyperthermia), mechanical effects (e.g., acoustic cavitation or through radiation force, acoustic streaming and other ultrasound induced forces), and chemical effects (via sonochemistry or by the activation of solutes by sonoluminescence). Ultrasound exposure conditions in these biomedical and in biological processes (e.g. ultrasound bioreactors) are limited by the need to increase the beneficial effects of ultrasound, while at the same time limiting the detrimental effects, such as apoptosis and cytolysis. Accordingly, the protecting molecules used to carry out the methods of the invention possess the ability to protect cells against ultrasound mediated cytolysis, without hindering ultrasound induced physical effects that could be utilized to create beneficial effects. The protecting solutes are surface active and possess at least one ‘‘carbohydrate unit’’ as described. The solutes include, but are not limited to: alkyl-b-Dthioglucopyranoside, alkyl-b-Dthiomaltopyranoside, alkyl-b-Dgalactopyranoside, alkyl-b-Dthiogalactopyranoside, or alkyl-b-Dmaltrioside, hexyl-b-D-glucopyranoside, heptyl-b-D-glucopyranoside, octyl-b-D- VerDate Aug<31>2005 15:30 Mar 23, 2007 Jkt 211001 glucopyranoside, nonyl-b-Dglucopyranoside, hexyl-b-Dmaltopyranoside, n-octyl-b-Dmaltopyranoside, n-octyl-b-Dthioglucopyranoside, 2-propyl-1-pentylb-D-maltopyranoside, methyl-6-O-(Nheptylcarbamoyl)-a-D-glucopyranoside, 3-cyclohexyl-1-propyl-b-D-glucoside, 6O-methyl-n-heptylcarboxyl-a-Dglucopyranoside. Inventors: Joe Z. Sostaric (NCI), Peter Riesz (NCI), et al. Publications: 1. Joe Z. Sostaric, Norio Miyoshi, Peter Riesz, William G. DeGraff and James B. Mitchell. n-Alkyl glucopyranosides completely inhibit ultrasound-induced cytolysis. Free Radic Biol Med. 2005 Dec 15;39(12):1539–1548. 2. Joe Z. Sostaric, Norio Miyoshi, Peter Riesz, William G. Degraff and James B. Mitchell. Complete inhibition of ultrasound-induced cytolysis in the presence of inertial cavitation. AIP Conf Proc. 2006 May 8;829:39–43. Patent Status: PCT Application No. PCT/US2005/037912 filed 19 Oct 2005, which published as WO 2006/045050 on 27 Apr 2006; claiming priority to 19 Oct 2004 (HHS Reference No. E–311– 2004/0–PCT–02). Licensing Status: Available for nonexclusive or exclusive licensing. Licensing Contact: Michael Shmilovich, Esq.; 301/435–5019; shmilovm@mail.nih.gov. Dated: March 12, 2007. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E7–5426 Filed 3–23–07; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant PO 00000 Frm 00054 Fmt 4703 Sfmt 4703 14125 applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel, Shared Resource Grant (R24). Date: April 23, 2007. Time: 1 p.m. to 4 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Keary A. Cope, PhD, Scientific Review Administrator, Review Branch/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7190, Bethesda, MD 20892–7924, 301–435– 2222, copeka@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 3.839, Blood Diseases and Resources Research, National Institutes of Health, HHS) Dated: March 12, 2007. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–1450 Filed 3–23–07; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel, Lung Disease Research Project. Date: April 12, 2007. Time: 2:30 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). E:\FR\FM\26MRN1.SGM 26MRN1

Agencies

[Federal Register Volume 72, Number 57 (Monday, March 26, 2007)]
[Notices]
[Pages 14124-14125]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-5426]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Rapid Universal and/or Type-Specific Assay for Clostridium Botulinum

    Description of Technology: The urgent need for a rapid diagnostic 
test capable of detecting all serotypes of C. botulinum is well known. 
Botulinum neurotoxins (BoNTs) are the most potent biological toxins 
known and are categorized as category A biodefense agents because of 
lethality and ease of production. Current diagnostic methods include 
clinical observation of symptoms that could be mistaken for other 
neurological conditions and a mouse protection bioassay that takes as 
long as four days and has a number of disadvantages. The subject 
technology utilizes unique PCR primers for the detection of the non-
toxin non-hemaglutinin (NTNH) gene of C. botulinum; this gene is highly 
conserved in all C. botulinum toxin types and subtypes. Thus, samples 
that contain botulinum can be determined regardless of serotype 
involved, providing a universal means of diagnosis. Further, the 
technology describes different PCR primers and flurogenic probes for a 
BoNT-specific assay. The type-specific assay can be used independently 
or in conjunction with the universal assay described above. The 
universal and type-specific assays were successfully used first to

[[Page 14125]]

identify positively botulinum DNA samples in a test of botulinum and 
non-botulinum clostridia species then to determine the toxin type. The 
diagnostic testing described by the subject technology requires 
significantly less time than the current gold standard diagnostic test.
    Applications: (1) Universal diagnostic test for C. botulinum; (2) 
Diagnostic test for C. botulinum capable of detecting all seven toxin 
types; (3) Combination diagnostic.
    Development Status: Fully developed.
    Inventors: Daniel C. Douek (VRC/NIAID) et al.
    Patent Status: U.S. Provisional Application No. 60/884,539 filed 11 
Jan 2007 (HHS Reference No. E-046-2007/0-US-01).
    Licensing Status: Available for non-exclusive or exclusive 
licensing.
    Licensing Contact: Susan Ano, Ph.D.; 301/435-5515; 
anos@mail.nih.gov.

Methods and Compositions for Protecting Cells From Ultrasound-Mediated 
Cytolysis

    Description of Invention: Available for licensing and commercial 
development are methods for protecting cells from ultrasound-mediated 
cytolysis. The in vitro exposure of cells to ultrasound and the 
therapeutic uses of ultrasound (e.g., sonoporation, thrombolysis, HIFU, 
sonophoresis, acoustic hemostasis) may induce changes in tissue state, 
including apoptosis and cytolysis, through thermal effects (e.g., 
hyperthermia), mechanical effects (e.g., acoustic cavitation or through 
radiation force, acoustic streaming and other ultrasound induced 
forces), and chemical effects (via sonochemistry or by the activation 
of solutes by sonoluminescence). Ultrasound exposure conditions in 
these biomedical and in biological processes (e.g. ultrasound 
bioreactors) are limited by the need to increase the beneficial effects 
of ultrasound, while at the same time limiting the detrimental effects, 
such as apoptosis and cytolysis. Accordingly, the protecting molecules 
used to carry out the methods of the invention possess the ability to 
protect cells against ultrasound mediated cytolysis, without hindering 
ultrasound induced physical effects that could be utilized to create 
beneficial effects. The protecting solutes are surface active and 
possess at least one ``carbohydrate unit'' as described. The solutes 
include, but are not limited to: alkyl-[beta]-D-thioglucopyranoside, 
alkyl-[beta]-D-thiomaltopyranoside, alkyl-[beta]-D-galactopyranoside, 
alkyl-[beta]-D-thiogalactopyranoside, or alkyl-[beta]-D-maltrioside, 
hexyl-[beta]-D-glucopyranoside, heptyl-[beta]-D-glucopyranoside, octyl-
[beta]-D-glucopyranoside, nonyl-[beta]-D-glucopyranoside, hexyl-[beta]-
D-maltopyranoside, n-octyl-[beta]-D-maltopyranoside, n-octyl-[beta]-D-
thioglucopyranoside, 2-propyl-1-pentyl-[beta]-D-maltopyranoside, 
methyl-6-O-(N-heptylcarbamoyl)-[alpha]-D-glucopyranoside, 3-cyclohexyl-
1-propyl-[beta]-D-glucoside, 6-O-methyl-n-heptylcarboxyl-[alpha]-D-
glucopyranoside.
    Inventors: Joe Z. Sostaric (NCI), Peter Riesz (NCI), et al.
    Publications:
    1. Joe Z. Sostaric, Norio Miyoshi, Peter Riesz, William G. DeGraff 
and James B. Mitchell. n-Alkyl glucopyranosides completely inhibit 
ultrasound-induced cytolysis. Free Radic Biol Med. 2005 Dec 
15;39(12):1539-1548.
    2. Joe Z. Sostaric, Norio Miyoshi, Peter Riesz, William G. Degraff 
and James B. Mitchell. Complete inhibition of ultrasound-induced 
cytolysis in the presence of inertial cavitation. AIP Conf Proc. 2006 
May 8;829:39-43.
    Patent Status: PCT Application No. PCT/US2005/037912 filed 19 Oct 
2005, which published as WO 2006/045050 on 27 Apr 2006; claiming 
priority to 19 Oct 2004 (HHS Reference No. E-311-2004/0-PCT-02).
    Licensing Status: Available for non-exclusive or exclusive 
licensing.
    Licensing Contact: Michael Shmilovich, Esq.; 301/435-5019; 
shmilovm@mail.nih.gov.

    Dated: March 12, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
 [FR Doc. E7-5426 Filed 3-23-07; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.